|Thursday, January 18, 2018||
Click the diagram above
to view the XBL Navigator.
XBL Enhances Key Services and Expands with New Laboratory in China
Plainsboro, NJ, May 20, 2009 - XenoBiotic Laboratories (XBL) continues to enhance its core services in the bioanalytical and ADME areas with the addition of a large molecule bioassay/cell-based assay group, Debra LIMS, QWBA and in-house NMR services. In addition, in summer 2009, XBL-China will open its doors.
Concurrently, XBL has opened a new laboratory for cell-based assays. Beginning in April, 2009, we will offer functional bioassays to detect neutralizing antibodies that will complement our immunochemistry services. In addition, we will offer a wide range of cell-based assays for drug potency evaluation, alternation of cell signaling pathway and pre-clinical toxicity profiling, including assays to measure cell viability, cell proliferation, apoptosis, and protein phosphorylation.
"For over 21 years, XBL has established itself as a premiere contract laboratory providing metabolism and bioanalytical services to the pharmaceutical and agrochemical industries. With the addition of a state-of-the-art laboratory and expertise to conduct Quantitative Whole Body Autoradiography (QWBA) studies, in-house NMR (500 MHz) and the industry standard Debra LIMS software, we now offer a complete and comprehensive package of services for Absorption, Distribution, Metabolism and Excretion (ADME) studies," according to Dennis Heller, Vice President of Pharmaceutical Development. "In addition, we recognized the expanding need for quantitative bioanalytical services for biologics (biotherapeutics and biomarkers) and as a result, invested in a new biologics group that will provide ELISA-based services for quantitative PK bioanalysis for biotherapeutics, immunogenicity screening and biomarker assays. Our biologics group is also developing key cell-based assays to screen the biological activity of macromolecules".
XBL-China's new 36,000 sq.ft laboratory in Nanjing has a 12,000 sq.ft vivarium and top of the line analytical instrumentation. With additional offices in Shanghai, XBL-China will provide bioanalytical and metabolism services to the exacting standards of XBL's New Jersey facility. According to Jinn Wu, President and Chief Executive Officer, "The initial goal for XBL-China is to offer GLP-level bioanalytical as well as discovery PK services to support drug development programs being conducted in Asian countries. Additional services such as synthetic chemistry, formulation services, Phase I clinical trial conduct, and SFDA registration are planned for the future. This is a significant expansion for XBL and will allow us to provide services to global pharmaceutical companies. An open house ceremony is planned for October, 2009."
About XBL. XenoBiotic Laboratories, Inc. (XBL) is a leading contract laboratory known for high quality science and project management, specializing in providing bioanalytical and metabolism services to the pharmaceutical, biotech, and agrochemical industries. Bioanalytical services are offered for small molecule and biologic (protein/peptide) drugs including method development/ validation and sample analysis in support of pre-clinical (GLP) and clinical studies. Metabolism services include a comprehensive set of preclinical radiolabel ADME, in vitro metabolism, CYP p450, and protein binding studies. XBL is FDA and EPA inspected, AAALAC accredited, and NRC, DEA, and USDA licensed. XBL. Invested in science. Invested in your success.
For further information, contact:
|©2005-2017, XenoBiotic Laboratories, Inc. All rights reserved.
Website created by Princeton Internet Group (PING)